Singh Prahlad R. exercised 57,039 shares at a strike of $76.83, sold $2,212,480 worth of shares (21,217 units at $104.28) and covered exercise/tax liability with 15,424 shares, increasing direct ownership by 25% to 103,414 units (SEC Form 4)

$PKI
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $PKI alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Singh Prahlad R.

(Last) (First) (Middle)
940 WINTER STREET

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
REVVITY, INC. [ RVTY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Please See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
02/05/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/05/2024 M 31,002(1) A $52.65(2) 114,018 D
Common Stock 02/05/2024 S 14,749 D $104.05(3) 99,269 D
Common Stock 02/05/2024 S 6,468 D $104.8(4) 92,801 D
Common Stock 02/05/2024 M 26,037(5) A $105.62 118,838 D
Common Stock 02/05/2024 F 11,209(6) D $105.62 107,629 D
Common Stock 02/05/2024 F 4,215(7) D $105.62 103,414 D
Common Stock 25,088 I By Singh Family Trust of 2021(8)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
NQ Stock Option (right to buy) $52.65(2) 02/05/2024 M 31,002 (9) 02/07/2024 Common Stock 31,002 $0 0 D
NQ Stock Option (right to buy) $104.635 02/05/2024 A 110,111 (10) 02/05/2031 Common Stock 110,111 $0 110,111 D
Explanation of Responses:
1. The transactions reported above in Table I include a cashless exercise of stock options. The cashless exercise for the stock options is reported in three lines. The first line of the cashless exercise transaction is coded M in column 3 of Table I and reports in column 4 the number of shares issuable upon exercise of the options had cash been paid to exercise the options, together with the exercise price with Code A for acquired. The second and third lines coded S in column 3 of Table I relate to the same cashless exercise on the first line in Table I and report in Column 4 the number of shares sold from the total number of shares issuable to pay for the cashless exercise of such options with Code D for disposed. The transaction reported in Table II line one above, reflects the disposition of the same stock options whose cashless exercise is disclosed in Table I above. The foregoing transactions were effected pursuant to a 10b5-1 trading plan adopted by Mr. Singh on August 4, 2023.
2. The Exercise Price included on the Form 4 filed on February 8, 2017 for the Reporting Person was incorrectly reported due to administrative error.
3. The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $103.55 to $104.54. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
4. The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $104.55 to $105.49. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
5. Shares of common stock issued upon vesting of performance-based restricted stock units in accordance with the terms of a Performance-based Restricted Stock Unit award originally granted on February 5, 2021.
6. These shares are being surrendered to satisfy a tax withholding obligation upon vesting of performance-based restricted stock units originally granted on February 5, 2021, as required by the Reporting Person's Performance-based Restricted Stock Unit Agreement.
7. These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 5, 2021, as required by the Reporting Person's Restricted Stock Agreement.
8. Securities held in an irrevocable trust for the sole benefit of the reporting person's children. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest, if any, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
9. This option became exercisable in three equal annual installments beginning on February 7, 2018, which was the first anniversary of the date on which the option was granted.
10. This option is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.
Remarks:
President, Chief Executive Officer and Director
/s/ John L. Healy (POA on file) for Prahlad R. Singh 02/07/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PKI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PKI

DatePrice TargetRatingAnalyst
12/19/2022$170.00Sector Weight → Overweight
KeyBanc Capital Markets
12/12/2022$135.00 → $170.00Neutral → Buy
Citigroup
12/6/2022$192.00 → $164.00Market Perform → Outperform
Cowen
11/28/2022$130.00 → $145.00Underweight → Equal Weight
Barclays
8/25/2022$175.00Neutral
Credit Suisse
8/18/2022$190.00 → $170.00Buy → Hold
Stifel
8/2/2022$178.00Buy → Neutral
BofA Securities
7/20/2022$160.00Buy
UBS
More analyst ratings

$PKI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Revvity Announces Financial Results for the First Quarter of 2023

    Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

     Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Ares Management Corporation Announces U.S. Direct Lending Origination Activity for the First Quarter and Last Twelve Months 2023

    Approximately $2.1 Billion in New Commitments Closed in the First Quarter and Approximately $23.5 Billion closed in the Last Twelve Months Ended March 31, 2023 Ares Management Corporation announced today that funds managed by its Credit Group (collectively "Ares") closed approximately $2.1 billion in U.S. direct lending commitments across 35 transactions during the first quarter of 2023 and approximately $23.5 billion in U.S. direct lending commitments across 189 transactions in the last twelve-month period ended March 31, 2023. Below is a description of selected transactions that Ares closed during the first quarter. Banyan Software Ares served as the agent, lead arranger and bookrun

    $ARES
    $PKI
    Investment Managers
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PKI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PKI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PKI
SEC Filings

See more

$PKI
Leadership Updates

Live Leadership Updates

See more
  • James Mock Joins Moderna as Chief Financial Officer

    CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective the same date but will remain as a consultant to the Company to assist with the transition."I am thrilled to welcome Jamey to Moderna's Executive Committee as our Chief Financial Officer. Moderna is at an exciting stage with a

    $MRNA
    $PKI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PerkinElmer Announces Finance Leadership Transition

    Max Krakowiak appointed new chief financial officer, replacing Jamey Mock PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity. The Company's Board of Directors has unanimously appointed Max Krakowiak to succeed Mr. Mock as its new senior vice president and CFO, effective as of September 6, 2022. Mr. Krakowiak is currently the Company's vice president of corporate finance, and has served in financial leadership roles of increasing responsibility for the last four years. "I would like to thank Jamey

    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

     Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021. PerkinElmer's strong revenue performance was driven by broad-based momentum across the portfolio. In total, non-COVID-19, or core, demand increased approximately 10% organically year-over-year, and COVID-19 related solutions contributed approximately $535 million of revenue in the first quarter. PerkinElmer will release its first quarter 2021 financial results a

    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PKI
Financials

Live finance-specific insights

See more
  • Revvity Announces Financial Results for the First Quarter of 2023

    Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

     Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PerkinElmer Board Declares Quarterly Dividend

    The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon

    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PKI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more